Mindray

Mindray, formally Mindray Bio-Medical Electronics Co., Ltd., is a Shenzhen-based Chinese medical-technology company that designs, manufactures, and sells equipment, systems, and accessories used in clinical care and laboratory diagnosis. Its portfolio serves both human and veterinary medicine and is organized around three principal business lines: Patient Monitoring & Life Support, In-Vitro Diagnostic Products, and Medical Imaging Systems. The company was established in Shenzhen in 1991 by seven former employees of Anke, including Li Xiting, Xu Hang, and Cheng Minghe. It initially developed by supplying medical electronics and diagnostic products to the domestic Chinese market. The company’s activities expanded from patient-monitoring equipment into broader hospital and laboratory workflows, including imaging, anesthesia, emergency-care, hematology, biochemistry, and other diagnostic applications. Mindray’s patient-monitoring and life-support activities include multi-parameter monitors, biotelemetry systems, anesthesia-delivery systems, defibrillators, electrocardiography equipment, pulse oximeters, hospital beds, mounting systems, and related information-technology solutions. Its in-vitro-diagnostics business provides instruments and consumables for analyzing blood, urine, and other bodily-fluid samples. Products in this area include hematology and biochemistry analyzers, reagents, microplate readers, and microplate washers. The medical-imaging business includes ultrasound systems and related equipment; the Resona ultrasound and BeneVision monitoring families are among the product lines associated with the brand. Mindray pursued international expansion through overseas subsidiaries, branch offices, direct sales, and strategic acquisitions. A notable step came in 2008, when it acquired the patient-monitoring division of Datascope Corporation for approximately $209 million, strengthening its presence outside China and adding established international monitoring capabilities. The company has been described as maintaining subsidiaries and branch offices across numerous countries, alongside an extensive domestic Chinese branch network. Mindray first became publicly traded in the United States, listing on the New York Stock Exchange in September 2006. It delisted in March 2016 as it prepared to return to China’s domestic capital market, and it was subsequently listed on the Shenzhen Stock Exchange in October 2018 under ticker 300760.SZ. The company has been recognized as one of China’s largest medical-device manufacturers and is positioned as a broad-line supplier combining medical technology, manufacturing scale, international distribution, and comparatively accessible products. The brand’s public record has also included a 2018 employment controversy. Mindray rescinded job offers made to 254 university students amid changing economic conditions, prompting public criticism. It reinstated the offers in early 2019, citing corporate social responsibility. In the same period, the company worked with Korle Bu Teaching Hospital in Ghana and donated a SAL 6000 analyzer intended to improve laboratory testing efficiency. These activities illustrate Mindray’s presence beyond commercial equipment sales, although the company’s central business remains the development and supply of medical devices, diagnostic instruments, software, and supporting accessories.

Mindray was founded in 1991 in Shenzhen, Guangdong, by seven former employees of Anke. Among the named founders were Li Xiting, Xu Hang, and Cheng Minghe. The company began by developing and supplying medical electronics and diagnostic products for China’s domestic healthcare market. Its early development was associated particularly with patient monitoring and other clinical equipment, but the business later broadened into imaging and laboratory diagnostics. Over time, Mindray developed three principal operating areas: Patient Monitoring & Life Support, In-Vitro Diagnostic Products, and Medical Imaging Systems. The patient-monitoring and life-support portfolio grew to include multi-parameter monitors, biotelemetry, anesthesia-delivery systems, defibrillators, electrocardiography machines, pulse oximeters, hospital beds, mounting systems, and healthcare information-technology solutions. Its in-vitro-diagnostics activities cover laboratory analysis of blood, urine, and other bodily fluids, with products including hematology analyzers, biochemistry analyzers, reagents, microplate readers, and microplate washers. The imaging business includes ultrasound systems, while the company also supplies equipment and accessories for veterinary applications. International expansion became an important part of Mindray’s development. In 2008, the company acquired the patient-monitoring division of Datascope Corporation for approximately $209 million. The transaction was intended to strengthen Mindray’s position outside China and expanded its access to established monitoring products and international markets. Mindray subsequently maintained subsidiaries and branch offices in a number of countries, together with a domestic network in China. By 2008, the company had been recognized as China’s largest medical-device manufacturer. Mindray’s capital-market history has included listings in both the United States and China. It listed on the New York Stock Exchange in September 2006. In March 2016, it delisted from the NYSE in preparation for an application to return to China’s A-share market. The company completed that transition in October 2018 by listing on the Shenzhen Stock Exchange under ticker 300760.SZ. The 2018 listing year also brought a public employment controversy. Mindray rescinded offers made to 254 university students, attributing the decision to changing economic conditions. The move drew public criticism, and the company reinstated the offers in early 2019 while referring to corporate social responsibility. The episode became part of the company’s public record but did not change its core business model. Mindray has also undertaken activities connected with healthcare capacity-building. In January 2019, it partnered with Korle Bu Teaching Hospital in Ghana to improve diagnostic patient care and donated a SAL 6000 analyzer to help increase the efficiency of local laboratory testing. In the present-day description supported by the available reference material, Mindray is an active multinational medical-technology manufacturer with a broad portfolio spanning bedside monitoring, life support, laboratory diagnostics, ultrasound and other medical-imaging applications. Its brand identity is built around supplying integrated clinical and diagnostic equipment to hospitals, laboratories, clinics, and veterinary users in China and international markets.

• 2019

  Diagnostic-care partnership in Ghana

  [1]Mindrayen.wikipedia.org

  Mindray partners with Korle Bu Teaching Hospital and donates a SAL 6000 analyzer to support laboratory testing.

• 2018

  Shenzhen Stock Exchange listing

  [1]Mindrayen.wikipedia.org

  Mindray lists on the Shenzhen Stock Exchange under ticker 300760.SZ.

• 2016

  NYSE delisting

  [1]Mindrayen.wikipedia.org

  Mindray delists from the New York Stock Exchange while preparing to seek a Chinese A-share listing.

• 2008

  Datascope patient-monitoring acquisition

  [1]Mindrayen.wikipedia.org

  Mindray acquires Datascope Corporation’s patient-monitoring division for approximately $209 million.

• 2008

  Recognition as China’s largest medical-device manufacturer

  [1]Mindrayen.wikipedia.org

  Mindray is recognized as the largest medical-device manufacturer in China.

• 2006

  New York Stock Exchange listing

  [1]Mindrayen.wikipedia.org

  Mindray becomes publicly traded on the New York Stock Exchange.

• 1991

  Mindray is founded in Shenzhen

  [1]Mindrayen.wikipedia.org

  Seven former Anke employees, including Li Xiting, Xu Hang, and Cheng Minghe, establish the company in Shenzhen, Guangdong.

A broad-line, technology-focused medical-device supplier serving hospitals, laboratories, clinics, and veterinary users. Mindray combines Chinese manufacturing scale with international operations across patient monitoring, life support, in-vitro diagnostics, and medical imaging.

• Patient monitoring and clinical information systems

  BeneVision

  BeneVision is a Mindray-associated family of patient-monitoring systems. The broader monitoring business covers multi-parameter bedside monitors, biotelemetry, clinical displays, mounting solutions, and related information-technology tools used to collect and present patient vital-sign data. The available reference material identifies BeneVision as a flagship offering but does not provide a complete model-by-model product history.

• Medical imaging

  Resona

  Resona is a Mindray ultrasound-system family used in medical imaging. It represents the company’s expansion beyond monitoring and laboratory products into diagnostic imaging. The available sources identify Resona as a flagship ultrasound offering but do not specify individual launch dates, current models, or detailed technical specifications.

• In-vitro diagnostics

  SAL 6000

  The SAL 6000 is a laboratory analyzer associated with Mindray’s in-vitro-diagnostics activities. In January 2019, the company donated one to Korle Bu Teaching Hospital in Ghana as part of a partnership intended to improve diagnostic patient care and local laboratory-testing efficiency.

• Patient monitoring and life support

  Patient Monitoring & Life Support portfolio

  This business line includes multi-parameter patient monitors, biotelemetry systems, anesthesia-delivery systems, defibrillators, ECG machines, pulse oximeters, hospital beds, mounting systems, and healthcare IT solutions. It serves clinical environments that need continuous monitoring, emergency support, anesthesia management, and associated workflow infrastructure.

• Laboratory diagnostics

  In-Vitro Diagnostic Products portfolio

  Mindray’s in-vitro-diagnostics business provides instruments and consumables for examining blood, urine, and other bodily-fluid samples. The portfolio includes semi-automated and fully automated hematology and biochemistry analyzers, reagents, microplate readers, and microplate washers for laboratories, clinics, and hospitals.

• Medical imaging

  Medical Imaging Systems portfolio

  The medical-imaging business includes ultrasound systems and related equipment. It forms one of Mindray’s three principal business lines and complements the company’s monitoring and laboratory-diagnostics products in hospital and clinical settings.

• 2018

  Rescinding offers to fresh graduates sparks employment agreement dispute; onboarding later resumed

  From the end of 2018 to early 2019, Mindray proposed terminating contracts with some fresh graduates who had already signed employment agreements, sparking controversy over employment and integrity. The company subsequently issued a statement welcoming the relevant fresh graduates to report for work as originally planned. This entry records the handling of the offers and subsequent adjustments, and does not treat the final destinations of all graduates as verified.

  Source

Read more

• 2019Korle Bu Teaching Hospital diagnostic-care partnership

  Ghana

  Mindray partnered with Korle Bu Teaching Hospital to support diagnostic patient care and donated a SAL 6000 analyzer intended to improve the efficiency of local laboratory testing.

  Outcome. The available reference states that the analyzer was donated to improve laboratory-test efficiency; it does not provide measured outcome data.

  Source

• 2018

  Shenzhen Stock Exchange relistingStrategy

  Background

  Following its NYSE delisting, Mindray pursued a listing in China’s A-share market.

  Action taken

  Mindray listed on the Shenzhen Stock Exchange in October 2018 under ticker 300760.SZ.

  Aftermath

  The company became publicly traded in China and continued operating as an active medical-technology manufacturer.

  Source

• 2018

  Reversal of withdrawn university job offersOther

  Background

  Mindray rescinded offers to 254 university students, citing changing economic conditions. The decision generated public criticism.

  Action taken

  The company reinstated the offers in early 2019 and referred to corporate social responsibility.

  Aftermath

  The offer reinstatement ended the immediate employment dispute described in the available reference material.

  Source

• 2016

  Withdrawal from the New York Stock ExchangeStrategy

  Background

  Mindray sought to reposition its public-market listing and apply for a return to China’s domestic A-share market.

  Action taken

  The company delisted from the New York Stock Exchange in March 2016.

  Aftermath

  Mindray subsequently completed a Shenzhen Stock Exchange listing in October 2018.

  Source

• 2008

  Acquisition of Datascope’s patient-monitoring divisionM&A

  Background

  Mindray sought to expand its international presence and strengthen its patient-monitoring business outside China.

  Action taken

  The company acquired the patient-monitoring division of Datascope Corporation for approximately $209 million.

  Aftermath

  The transaction expanded Mindray’s international monitoring capabilities and supported its overseas growth.

  Acquisition price. $209 million (2008)

  Source

• 2021.09.22

  Mindray completes acquisition of HyTest[9]迈瑞医疗完成收购海肽生物news.pedaily.cn

  Mindray completed the transaction to acquire 100% of HyTest Invest Oy and its subsidiaries for €532 million. Mindray Netherlands now directly or indirectly holds all of their equity.

• 2021.05.20

  Reported2021.05.20

  Mindray sponsors NTI 2021 educational sessions[10]迈瑞赞助2021年NTI教育课程prweb.com

  Mindray North America announced that Mindray-sponsored educational sessions would take place at the National Teaching Institute & Critical Care Exposition 2021, including sessions by critical care and clinical education speakers.

• 2021.01.19

  Reported2021.01.19

  Mindray introduces ePM patient monitor series in North America[11]Mindray 在北美推出 ePM 患者监护仪系列prweb.com

  Mindray introduced the ePM series of continuous, multi-parameter patient monitors for ambulatory surgery centers and out-of-hospital settings in North America.

• 2020.08.27

  Reported2020.08.27

  Mindray reports first-half 2020 results[12]迈瑞医疗披露2020年半年度业绩finance.sina.com.cn

  Mindray disclosed its 2020 half-year results, reporting revenue of RMB 10.564 billion and net profit attributable to shareholders of RMB 3.454 billion for January through June.

Read more

1. 1Mindrayen.wikipedia.org
2. 2Mindray official websitemindray.com
3. 3Mindray North America - Hospital Equipmentmindray.com
4. 4Discover Innovative Healthcare Equipment Solutions | Mindraymindray.com
5. 5Aboutmindray.com
6. 6About Us: Corporate Information and Culture - Mindraymindray.com
7. 7Rescinding offers to fresh graduates sparks employment agreement dispute; onboarding later resumedm.yicai.com
8. 8Rescinding offers to fresh graduates sparks employment agreement dispute; onboarding later resumedyicai.com
9. 9迈瑞医疗完成收购海肽生物news.pedaily.cn
10. 10迈瑞赞助2021年NTI教育课程prweb.com
11. 11Mindray 在北美推出 ePM 患者监护仪系列prweb.com
12. 12迈瑞医疗披露2020年半年度业绩finance.sina.com.cn